Ulf Schönermarck

3.7k total citations · 1 hit paper
70 papers, 2.3k citations indexed

About

Ulf Schönermarck is a scholar working on Pulmonary and Respiratory Medicine, Nephrology and Immunology. According to data from OpenAlex, Ulf Schönermarck has authored 70 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 22 papers in Nephrology and 13 papers in Immunology. Recurrent topics in Ulf Schönermarck's work include Vasculitis and related conditions (19 papers), Renal Diseases and Glomerulopathies (13 papers) and Renal Transplantation Outcomes and Treatments (10 papers). Ulf Schönermarck is often cited by papers focused on Vasculitis and related conditions (19 papers), Renal Diseases and Glomerulopathies (13 papers) and Renal Transplantation Outcomes and Treatments (10 papers). Ulf Schönermarck collaborates with scholars based in Germany, United States and United Kingdom. Ulf Schönermarck's co-authors include Wolfgang L. Gross, Dieter E. Jenne, Volker Brinkmann, Kai Kessenbrock, Zena Werb, Hermann-Josef Gröne, Walter Back, Markus Krumbholz, Elena Csernok and Michael Fischereder and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ulf Schönermarck

67 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Netting neutrophils in autoimmune small-vessel vasculitis

2009 1.3k citations Ulf Schönermarck et al. profile →

Peers

Countries citing papers authored by Ulf Schönermarck

Since Specialization

Citations

This map shows the geographic impact of Ulf Schönermarck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulf Schönermarck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulf Schönermarck more than expected).

Fields of papers citing papers by Ulf Schönermarck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulf Schönermarck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulf Schönermarck. The network helps show where Ulf Schönermarck may publish in the future.

Co-authorship network of co-authors of Ulf Schönermarck

This figure shows the co-authorship network connecting the top 25 collaborators of Ulf Schönermarck. A scholar is included among the top collaborators of Ulf Schönermarck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulf Schönermarck. Ulf Schönermarck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study 2025 ·European Journal of Internal Medicine ·Elisabetta Goni, Jens Vikse, Marco Lanzillotta, Bjørg‐Tilde Svanes Fevang, Øyvind Midtvedt, (unknown), Veronica Batani, (unknown), Georg Beyer, Lorenzo Dagna, Øyvind Molberg, Katrine Brække Norheim, Ulf Schönermarck, Ivonne Regel, Julia Mayerle, Anna‐Maria Hoffmann‐Vold, Emanuel Della‐Torre	1
2	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS 2022 ·Nephrology Dialysis Transplantation ·Kate Stevens, Eleni Frangou, Jae Il Shin, Hans‐Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Häuser, Kerstin Westman, Gema Fernández‐Juárez, Jürgen Floege, Dimitrios Goumenos, Kültiğin Türkmen, Cees van Kooten, Stephen P. McAdoo, Vladimı́r Tesař, Mårten Segelmark, Duvuru Geetha, David Jayne, Andreas Kronbichler	17
3	Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in Germany 2022 ·Frontiers in Medicine ·Melissa Grigorescu, Stephan Kemmner, Ulf Schönermarck, (unknown), (unknown), (unknown), Ben Illigens, Timo Siepmann, Bruno Meiser, Markus Guba, Michael Fischereder, (unknown)	3
4	Thrombotische Mikroangiopathien in der operativen Intensivmedizin unter besonderer Berücksichtigung des atypischen hämolytisch-urämischen Syndroms 2022 ·Die Anaesthesiologie ·Sebastian Albrecht, (unknown), Ulf Schönermarck, (unknown)	0
5	Drug-induced CYP-induction as therapy for tacrolimus intoxication 2022 ·PubMed ·(unknown), Alexander Holderied, Ulf Schönermarck, Volker Vielhauer, Hans‐Joachim Anders, Michael Fischereder	5
6	HLA-DRB1∗16 and -DQB1∗05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients 2022 ·Pancreatology ·Elisabetta Goni, Ivonne Regel, Ujjwal Mukund Mahajan, Antonio Amodio, (unknown), Georg Beyer, Raffaella Alessia Zuppardo, Milena Di Leo, Marco Lanzillotta, Francesco Bonatti, Teresa Kauke, Andrea Dick, Frank Ulrich Weiß, Ulf Schönermarck, Markus M. Lerch, Luca Frulloni, Giulia Martina Cavestro, Julia Mayerle	5
7	Thrombotic microangiopathy following aortic surgery with hypothermic circulatory arrest: a single-centre experience of an underestimated cause of acute renal failure 2021 ·Interactive Cardiovascular and Thoracic Surgery ·(unknown), (unknown), (unknown), Michael Fischereder, Christian Hagl, Ulf Schönermarck, Maximilian Pichlmaier, Sven Peterß, Dominik Jóskowiak	3
8	Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum 2021 ·Journal of Pharmaceutical and Biomedical Analysis ·Katharina Habler, Mathias Brügel, Daniel Teupser, Uwe Liebchen, Christina Scharf, Ulf Schönermarck, Michael Vogeser, Michael Paal	70
9	Severe Acute Kidney Injury in Cardiovascular Surgery: Thrombotic Microangiopathy as a Differential Diagnosis to Ischemia Reperfusion Injury. A Retrospective Study 2020 ·Journal of Clinical Medicine ·Melissa Grigorescu, (unknown), (unknown), Dominik Jóskowiak, Sven Peterß, Stephan Kemmner, Maximilian Pichlmaier, Christian Hagl, Michael Fischereder, Ulf Schönermarck	5
10	Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission 2020 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), Ulf Schönermarck, Hanna Mannell, Christian G. Stief, Joerg Hasford, (unknown)	6
11	Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study 2019 ·Orphanet Journal of Rare Diseases ·Wolfgang Miesbach, Jan Menne, Martin Bommer, Ulf Schönermarck, Thorsten Feldkamp, Martin Nitschke, Timm H. Westhoff, Felix S. Seibert, Rainer P. Woitas, (unknown), Michael Wolf, Stefan Walzer, (unknown)	27
12	Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort 2015 ·PLoS ONE ·Fabian Schnitzler, Matthias Friedrich, Johannes Stallhofer, Ulf Schönermarck, Michael Fischereder, Antje Habicht, Nazanin Karbalai, Christiane Wolf, (unknown), Torsten Olszak, Florian Beigel, Cornelia Tillack, Burkhard Göke, Roman Zachoval, Gerald Denk, Markus Guba, Christian Rust, Norbert H. Grüner, Stephan Brand	26
13	Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit 2014 ·Clinical Kidney Journal ·(unknown), (unknown), Ulf Schönermarck	0
14	Headaches After Renal Transplantation—A Case Report 2013 ·Transplantation Proceedings ·(unknown), (unknown), Antje Habicht, Michael Fischereder, Ulf Schönermarck	2
15	Chronic kidney disease is not associated with a higher risk for mortality or acute kidney injury in transcatheter aortic valve implantation 2012 ·Nephrology Dialysis Transplantation ·(unknown), (unknown), Philipp Lange, Kenneth L. Kehl, (unknown), Ulf Schönermarck, Gerhard Steinbeck, Michael Fischereder, Peter Boekstegers	39
16	Transcatheter Aortic Valve Implantation in Dialysis Patients 2012 ·Nephron Clinical Practice ·(unknown), (unknown), Philipp Lange, Christian Kupatt, Gerhard Steinbeck, Michael Fischereder, Ulf Schönermarck	20
17	Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil 2008 ·Transplant International ·Markus Guba, Markus Rentsch, C. Wimmer, (unknown), Wolf‐Dieter Illner, Ulf Schönermarck, W. Land, Karl‐Walter Jauch, Helmut Arbogast	16
18	Cholesterol atheroembolic disease in kidney allografts case report and review of the literature 2006 ·Clinical Nephrology ·Ulf Schönermarck, Markus Guba, (unknown), (unknown), Helmut Arbogast, Thomas Bosch	5
19	Comparative evaluation of oxidative and antioxidative capacity during high-flux hemodialysis using two different membranes 2006 ·Clinical Nephrology ·Ulf Schönermarck, (unknown), Freja Ebeling, Matthias Heydenreich, G Hillebrand, W. Samtleben	4
20	Vascular Access for Apheresis in Intensive Care Patients 2003 ·Therapeutic Apheresis and Dialysis ·Ulf Schönermarck, Thomas Bosch	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact